✦ LIBER ✦

Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha

✍ Scribed by Mitchell L. Shiffman; Jennifer Salvatore; Sarah Hubbard; Angie Price; Richard K. Sterling; R. Todd Stravitz; Velimir A. Luketic; Arun J. Sanyal

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 314 KB
Volume: 46
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.21712

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of peginterferon alp

Efficacy and safety of peginterferon alpha-2a/ribavirin in treatment-naive Cameroonian patients with chronic hepatitis C

✍ Richard Njouom; Michèle Tagni Sartre; Isabelle Timba; Eric Nerrienet; Patrice Tc 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 1 views

## Abstract Data were examined from a day‐to‐day clinical practice in Yaounde, Cameroon to evaluate the efficacy and safety of peginterferon alfa‐2a and ribavirin in treatment‐naive Cameroonian patients with chronic hepatitis C. Ninety adults with chronic hepatitis C (mean age, 53 ± 8 years; 79% ma

Treatment of insulin resistance with met

Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin

✍ Manuel Romero-Gómez; Moisés Diago; Raúl J. Andrade; José L. Calleja; Javier Salm 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 309 KB 👁 1 views

Insulin resistance affects sustained virological response (SVR) in chronic hepatitis C. To know whether adding metformin to standard antiviral treatment improves SVR, we conducted a prospective, multicentered, randomized, double-blinded, placebo-controlled trial in 19 Spanish hospitals, including 12

Impact of weight-based ribavirin with pe

Impact of weight-based ribavirin with peginterferon alfa-2b in african americans with hepatitis C virus genotype 1

✍ Ira M. Jacobson; Robert S. Brown Jr; Jonathan McCone; Martin Black; Clive Albert 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 313 KB 👁 1 views

Brass, 14 for the WIN-R Study Group WIN-R (Weight-based dosing of pegINterferon alfa-2b and Ribavirin) was a multicenter, randomized, open-label, investigator-initiated trial involving 236 community and academic sites in the United States, comparing response to pegylated interferon (PEG-IFN) alfa-2b

Risk factors for infection during treatm

Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C

✍ Robert Roomer; Bettina E. Hansen; Harry L. A. Janssen; Robert J. de Knegt 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB 👁 2 views

Neutropenia during treatment with peginterferon alfa and ribavirin for chronic hepatitis C virus (HCV) infection is a common cause of dose reductions of peginterferon alfa. These reductions are performed to prevent bacterial and fungal infections, which are common during HCV treatment and can be att

Peginterferon alfa-2b plus ribavirin tre

Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C

✍ Stefan Wirth; Heidrun Pieper-Boustani; Thomas Lang; Antje Ballauff; Ulrike Kullm 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB 👁 2 views

Peginterferon plus ribavirin is standard therapy for adults with chronic hepatitis C. As no data are available for children, the aim of the study was to evaluate the efficacy and tolerability of peginterferon alfa-2b in combination with ribavirin in chronically infected children. Genotypes, alanine

Treatment extension to 72 weeks of pegin

Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1–infected slow responders

✍ Brian L. Pearlman; Carole Ehleben; Sophia Saifee 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 216 KB 👁 1 views

In hepatitis C virus (HCV) genotype 1 infection, the duration of interferon-based therapy is a critical determinant in achieving sustained virologic response (SVR). Slow or late responders to peginterferon and ribavirin may benefit from an extended treatment course. We sought to determine if therapy